Topic: vaccine manufacturing
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
Here is some other vaccine news of note for the week.
China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.
The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.
Sanofi will invest more than $200 million in a new plant in France to produce its newest flu vaccine, VaxigripTetra.
GlaxoSmithKline opened its new $56.6 million vaccines plant in Montrose, Scotland, that will manufacture sterile aluminum salts.
Shire has found a buyer for a former Baxter vaccine plant in Europe as it continues its manufacturing consolidation after buying Baxalta.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
Takeda’s plan to launch a Hib vaccine in Japan has ended in smoke as GlaxoSmithKline has terminated production of Vaxem Hib.
Samsung won FDA nod for a Remicade biosim, Otsuka expanded anemia deal with Akebia, analysts are cautiously optimistic about China's foreign drug proposal.